iBio (IBIO) Assets Average (2011 - 2026)
iBio (IBIO) posted quarterly Assets Average of $75.1 million for Q1 2026, up 268.2% year-over-year from $20.4 million in Q1 2025, and up 16.86% quarter-over-quarter from $64.3 million in Q4 2025.
iBio (IBIO) Assets Average (2011 - 2026) Analysis & Trends
iBio (IBIO) has reported Assets Average for 16 consecutive years, with $75.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 268.2% year-over-year to $75.1 million; the TTM figure through Mar 2026 stood at $75.1 million (up 268.2% YoY), while the FY2025 annual figure was $26.0 million, down 25.77% from the prior year.
- Assets Average climbed to $75.1 million in Q1 2026 per IBIO's latest filing, from $64.3 million in the prior quarter.
- Across five years, Assets Average topped out at $120.9 million in Q1 2022 and bottomed at $20.4 million in Q1 2025.
- Historically, Assets Average has averaged $53.6 million across 5 years, with a median of $42.8 million in 2023.
- Annual changes were most pronounced in 2023 — Assets Average plunged 60.22% — and 2026, when it surged 268.2%.
- iBio's Assets Average stood at $68.2 million in 2022, then sank by 47.42% to $35.8 million in 2023, then slumped by 35.55% to $23.1 million in 2024, then surged by 178.16% to $64.3 million in 2025, then climbed by 16.86% to $75.1 million in 2026.
- Business Quant data shows IBIO's Assets Average at $75.1 million in Q1 2026, $64.3 million in Q4 2025, and $43.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | iBio | 175.21 Mn | 175.21 Mn | - | 75.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.11 Mn |
| Dec 31, 2025 | 64.27 Mn |
| Sep 30, 2025 | 43.67 Mn |
| Jun 30, 2025 | 21.14 Mn |
| Mar 31, 2025 | 20.40 Mn |
| Dec 31, 2024 | 23.11 Mn |
| Sep 30, 2024 | 26.63 Mn |
| Jun 30, 2024 | 39.44 Mn |
| Mar 31, 2024 | 42.09 Mn |
| Dec 31, 2023 | 35.85 Mn |
| Sep 30, 2023 | 39.44 Mn |
| Jun 30, 2023 | 42.80 Mn |
| Mar 31, 2023 | 48.09 Mn |
| Dec 31, 2022 | 68.18 Mn |
| Sep 30, 2022 | 91.99 Mn |
| Jun 30, 2022 | 107.39 Mn |
| Mar 31, 2022 | 120.91 Mn |
| Dec 31, 2021 | 135.09 Mn |
| Sep 30, 2021 | 145.35 Mn |
| Jun 30, 2021 | 144.83 Mn |